Kyu‐pyo Kim
YOU?
Author Swipe
View article: Embolization with Quick-Soluble Gelatin Sponge Particles for Lower Gastrointestinal Bleeding: A Multicenter Study
Embolization with Quick-Soluble Gelatin Sponge Particles for Lower Gastrointestinal Bleeding: A Multicenter Study Open
Background and Objectives: Transarterial embolization (TAE) serves as a valuable alternative for gastrointestinal bleeding when endoscopy fails or is inaccessible. Quick-soluble gelatin sponge particles (QS-GSPs) dissolve rapidly and may r…
View article: Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer
Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer Open
Importance Limited prospective data exist on the role of adding taxane to standard chemotherapy in the first-line treatment of advanced biliary tract cancers, especially in the Asian population, where biliary tract cancers are most prevale…
View article: Embolization with Quick-Soluble Gelatin Sponge Particles for Lower Gastrointestinal Bleeding: A Multicenter Study
Embolization with Quick-Soluble Gelatin Sponge Particles for Lower Gastrointestinal Bleeding: A Multicenter Study Open
Background and Objectives: Transcatheter arterial embolization (TAE) serves as a valuable alternative for gastrointestinal bleeding when endoscopy fails or is inaccessible. Quick-soluble gelatin sponge particles (QS-GSP) dissolve rapidly a…
View article: Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia
Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia Open
Systemic therapies, primarily cytotoxic chemotherapies, are the mainstay treatment option for pancreatic ductal adenocarcinoma (PDAC) alongside surgery. Several guidelines exist for managing PDAC within Asia, but recommendations for system…
View article: Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab Open
Introduction: Atezolizumab-bevacizumab (Atezo-Bev) has become the standard first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, data on subsequent treatment after Atezo-Bev failure are lacking. We a…
View article: Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the <scp>NIFTY</scp> Trial
Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the <span>NIFTY</span> Trial Open
Background Numerous studies have explored the role of vitamin D in various cancers; however, its impact on advanced biliary tract cancers (BTC) within a prospective cohort remains to be investigated. This preplanned subgroup analysis of th…
View article: Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma Open
NCT03079427.
View article: Prognostic value of tumor-infiltrating lymphocytes in distal extrahepatic bile duct carcinoma
Prognostic value of tumor-infiltrating lymphocytes in distal extrahepatic bile duct carcinoma Open
sTILs were superior to iTILs in predicting survival, and it was shown to be a strong prognosticator for DBDC patients regardless of the stage. The utility of sTILs may extend beyond prognostication to aid in predicting therapeutic response…
View article: Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials Open
PurposeWhile fluoropyrimidine-based chemotherapy regimens are recommended second-line treatment for patients with advanced biliary tract cancer (BTC), there have been no studies comparing different regimens head-to-head.Materials and Metho…
View article: Data from Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
Data from Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer Open
Purpose:Recently, anti-programmed cell death-1/anti-programmed cell death ligand-1 (anti-PD1/L1) immunotherapy has been demonstrated for its efficacy when combined with cytotoxic chemotherapy in randomized phase 3 trials for advanced bilia…
View article: Supplementary Data1 from Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
Supplementary Data1 from Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer Open
Supplementary Methods; Supplementary Figs. 1-6; Supplementary Tables 1-4.
View article: Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma
Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma Open
Purpose Clinical outcomes of surgery after neoadjuvant chemotherapy have not been investigated for locally advanced pancreatic cancer (LAPC), despite well-established outcomes in borderline resectable pancreatic cancer (BRPC). This study a…
View article: Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study Open
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with treatment outcomes closely tied to liver function. This study evaluates the prognostic utility of the albumin-bil…
View article: Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer
Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer Open
Background: There is no standardized assessment for evaluating response although neoadjuvant chemotherapy (NAT) is widely accepted for borderline resectable or locally advanced pancreatic cancer (BRPC or LAPC). This study was aimed to eval…
View article: Comparison of surgical outcomes for hip fracture between older patients with and without cancer: a propensity score matching analysis
Comparison of surgical outcomes for hip fracture between older patients with and without cancer: a propensity score matching analysis Open
Research on the treatment outcomes and mortality of patients with cancer and hip fractures remains limited. We aimed to assess the treatment outcomes and mortality in older patients with cancer and hip fractures. We retrospectively reviewe…
View article: Epidemiology and Outcomes of Non–Small Cell Lung Cancer in South Korea
Epidemiology and Outcomes of Non–Small Cell Lung Cancer in South Korea Open
Importance Valuable evidence regarding clinical characteristics, treatments, and outcomes for non–small cell lung cancer (NSCLC) is limited to individual hospital databases or national-level registries. The common data and federated analys…
View article: Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for immune checkpoint inhibitors in advanced biliary tract cancer
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for immune checkpoint inhibitors in advanced biliary tract cancer Open
The combination of anti-PD-1/L1 with gemcitabine and cisplatin (GemCis) has recently shown significant survival benefits in randomized phase 3 trials for advanced biliary tract cancer (BTC). However, no biomarker predictive of benefit has …
View article: PP492 177Lu-DOTATATE peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumors: Asian retrospective analysis
PP492 177Lu-DOTATATE peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumors: Asian retrospective analysis Open
View article: Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma Open
Purpose Modified FOLFIRINOX (mFOLFIRINOX) is one of the standard first-line therapies in patients with borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC). However, there is no globally…
View article: Organ-specific Response with First-line Atezolizumab-Bevacizumab versus Lenvatinib for Patients with Advanced Hepatocellular Carcinoma
Organ-specific Response with First-line Atezolizumab-Bevacizumab versus Lenvatinib for Patients with Advanced Hepatocellular Carcinoma Open
Background:Immune checkpoint inhibitor (ICI)-based treatments have become the mainstay of first-line treatment for unresectable hepatocellular carcinoma (HCC), but there has been a concern that intrahepatic HCC lesions may be less responsi…
View article: Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection
Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection Open
Purpose There are no reliable biomarkers to guide treatment for patients with borderline resectable pancreatic cancer (BRPC) in the neoadjuvant setting. We used plasma circulating tumor DNA (ctDNA) sequencing to search biomarkers for patie…
View article: Data from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Data from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy Open
Clinical trials are evaluating the efficacy of anti-TIGIT for use as single-agent therapy or in combination with programmed death 1 (PD-1)/programmed death-ligand 1 blockade. How and whether a TIGIT blockade will synergize with immunothera…
View article: Data from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Data from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy Open
Clinical trials are evaluating the efficacy of anti-TIGIT for use as single-agent therapy or in combination with programmed death 1 (PD-1)/programmed death-ligand 1 blockade. How and whether a TIGIT blockade will synergize with immunothera…
View article: Supplementary Figures from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Supplementary Figures from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy Open
Containing Supplementary Figures S1 - S12
View article: Supplementary Figures from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Supplementary Figures from CD226<sup>hi</sup>CD8<sup>+</sup> T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy Open
Containing Supplementary Figures S1 - S12
View article: Supplementary Figure 2 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 2 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of FGFR3 or FGFR4 on the sensitivities of PHA665752-treated HCC cell lines.
View article: Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
The MET receptor tyrosine kinase, the receptor for hepatocyte growth factor (HGF), has been implicated in cancer growth, invasion, migration, angiogenesis, and metastasis in a broad variety of human cancers, including human hepatocellular …
View article: Supplementary Figure 4 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 4 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of c-MET on phospho-MET and FGFR negative-HCC cell lines.
View article: Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Inhibition of cell growth and downstream signaling molecules of HCC cell lines by MET or pan-FGFR inhibitor.
View article: Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
The MET receptor tyrosine kinase, the receptor for hepatocyte growth factor (HGF), has been implicated in cancer growth, invasion, migration, angiogenesis, and metastasis in a broad variety of human cancers, including human hepatocellular …